GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy
The next waves might not be as colossal, but they still hold potential for investors navigating these waters.
Læs hele blogindlægget fra Tommy Carstensen
https://blog.midgardfinance.com/2025/01/26/the-next-wave-of-obesity-drugs-opportunities-and-risks-for-investors/
The next waves might not be as colossal, but they still hold potential for investors navigating these waters.
Læs hele blogindlægget fra Tommy Carstensen
https://blog.midgardfinance.com/2025/01/26/the-next-wave-of-obesity-drugs-opportunities-and-risks-for-investors/
